The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Official Title: A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
Study ID: NCT05067140
Brief Summary: A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Clinical Trial Site, Duarte, California, United States
Clinical Trial Site, Fresno, California, United States
Clinical Trial Site, La Jolla, California, United States
Clinical Trial Site, Orange, California, United States
Clinical Trial Site, Santa Monica, California, United States
Clinical Trial Site, New Haven, Connecticut, United States
Clinical Trial Site, Washington, District of Columbia, United States
Clinical Trial Site, Lake Mary, Florida, United States
Clinical Trial Site, Chicago, Illinois, United States
Clinical Trial Site, New Orleans, Louisiana, United States
Clinical Trial Site, Baltimore, Maryland, United States
Clinical Trial Site, Boston, Massachusetts, United States
Clinical Trial Site, Detroit, Michigan, United States
Clinical Trial Site, Buffalo, New York, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, Philadelphia, Pennsylvania, United States
Clinical Trial Site, Pittsburgh, Pennsylvania, United States
Clinical Trial Site, Myrtle Beach, South Carolina, United States
Clinical Trial Site, Nashville, Tennessee, United States
Clinical Trial Site, San Antonio, Texas, United States
Clinical Trial Site, Charlottesville, Virginia, United States
Clinical Trial Site, Fairfax, Virginia, United States
Clinical Trial Site, Madison, Wisconsin, United States